Adma Biologics (ADMA) Leases (2016 - 2025)
Adma Biologics (ADMA) has disclosed Leases for 11 consecutive years, with $6.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 22.98% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, down 22.98%, and an annual FY2025 reading of $6.6 million, down 22.98% over the prior year.
- Leases was $6.6 million for Q4 2025 at Adma Biologics, down from $9.3 million in the prior quarter.
- Across five years, Leases topped out at $10.6 million in Q2 2022 and bottomed at $6.2 million in Q1 2021.
- Average Leases over 5 years is $8.7 million, with a median of $9.1 million recorded in 2024.
- The sharpest move saw Leases skyrocketed 140.42% in 2021, then decreased 22.98% in 2025.
- Year by year, Leases stood at $7.3 million in 2021, then soared by 44.37% to $10.5 million in 2022, then decreased by 8.11% to $9.6 million in 2023, then fell by 10.39% to $8.6 million in 2024, then fell by 22.98% to $6.6 million in 2025.
- Business Quant data shows Leases for ADMA at $6.6 million in Q4 2025, $9.3 million in Q3 2025, and $9.0 million in Q2 2025.